Cargando…
SAT-LB6 First Human Trial of an Oral Native Testosterone Shows Physiological Levels of Testosterone and Dht in Both Fasted and Fed State in Hypogonadal Men
Introduction: The prevalence of male hypogonadism is estimated to be 6% in the USA (1). Current therapies have limited acceptability: gels can be messy and risk inadvertent dosing of others; injections are painful; and oral testosterone undecanoate (TU) delivers variable testosterone levels, require...
Autores principales: | Newell-Price, John D C, Porter, John, Quirke, Jo, Daniel, Eleni, Mumdzic, Enis, Ross, Richard John M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209306/ http://dx.doi.org/10.1210/jendso/bvaa046.2108 |
Ejemplares similares
-
SAT-030 The Barnsley Diabetes Hypogonadal Questionnaire (BDHQ) - Validation for the Clinical Use to Support the Diagnosis of Testosterone Deficiency in Men with Type 2 Diabetes (T2D)
por: Mumdzic, Enis, et al.
Publicado: (2020) -
An oral lipidic native testosterone formulation that is absorbed independent of food
por: Newell-Price, John, et al.
Publicado: (2021) -
SAT-051 Effects of Testosterone Replacement on Glycemic Control and Other Cardiovascular Risk Factors in Hypogonadal Men with Uncontrolled Type 2 Diabetes (Stride Study): Design, Implementation and Baseline Data
por: Rao, Preethi Mohan, et al.
Publicado: (2020) -
SUN-237 Higher Doses of Testosterone Gel Required in Hypogonadal Men with Obesity to Achieve Therapeutic Replacement - Advice on Dose Titration
por: Mumdzic, Enis, et al.
Publicado: (2019) -
RF34 | PMON263 Study of Testosterone Replacement in Hypogonadal Men With Uncontrolled Type 2 Diabetes – a Randomised Double Blinded Placebo Controlled Trial (STRIDE Study)
por: Mohan Rao, Preethi, et al.
Publicado: (2022)